Search

Learn about how to cope with grief during the holidays from MSK Experts.

… Tuesday, December 13, 2016 Summary MSK experts provide advice on how to cope with grief during the holiday season. It’s important to reevaluate rituals, seek support, and remain aware of your own mental health. Highlights Seek support: Surround yourself with others who’ve experienced what you have. Accept

Expand your knowledge of melanoma with these surprising facts.

… Tuesday, May 11, 2021 Summary Does melanoma always develop from a mole? Can melanoma be pink? Read on to expand your knowledge of the disease. Compared to other cancers, melanoma  may seem fairly straightforward. But there’s more to this disease than meets the eye. Dermatologist Ashfaq Marghoob of the

Adding idelalisib (Zydelig®) to a standard chemotherapy regimen of bendamustine and rituximab (BR) significantly increases progression-free survival (PFS) and overall survival (OS) in patients with relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) as compared with BR alone, according to new findings presented by a Memorial Sloan Kettering (MSK) investigator on behalf of his international co-investigators. Results from the phase III study were presented as part of the press program at this year’s American Society of Hematology annual meeting.

… Sunday, December 6, 2015 Adding idelalisib (Zydelig®) to a standard chemotherapy regimen of bendamustine and rituximab (BR) significantly increases progression-free survival (PFS) and overall survival (OS) in patients with relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) as compared

A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial.

… Sunday, December 7, 2014 A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial. The study, led by Eytan M. Stein, MD , a medical oncologist at Memorial Sloan Kettering Cancer Center, was presented today

Researchers at MSK have been at the forefront of developing new treatments for advanced melanoma for many years. Learn more about the latest therapies.

… Monday, July 8, 2024 In recent years, advanced melanoma (a type of skin cancer) has been transformed from a disease that was almost always fatal to one that often can be brought under control for years, or even cured. Thanks to new drugs, people with advanced disease have a five-year survival rate of

Learn from neurosurgeon Viviane Tabar about the standard treatment for glioblastoma, which involves surgery, chemotherapy, and radiation.

… Saturday, August 25, 2018 Summary The passing of Senator John McCain has focused attention on the aggressive brain cancer called glioblastoma. Viviane Tabar, Chief of Neurosurgery, explains how the disease develops and how MSK treats people with glioblastoma and other brain cancers. Editor’s Note: This

State-of-the-art facility will be reduced by 76 feet while continuing to meet increasing demand for cancer care.

… Friday, May 30, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced an updated design for MSK’s forthcoming Kenneth C. Griffin Pavilion at MSK, which includes a reduction in the originally proposed height of the building by 76 feet. The newly-designed Griffin Pavilion, slated for construction

Learn about the latest advances in lung cancer treatment at MSK.

… Friday, November 15, 2024 Lung cancer is the second-most common cancer and remains the leading cause of cancer death in the United States. But a variety of new treatments, many of them developed or tested at Memorial Sloan Kettering Cancer Center (MSK), are helping to bring down the number of deaths.

Conozca los últimos avances en el tratamiento contra el cáncer pulmonar en MSK.

… Friday, November 15, 2024 El cáncer pulmonar es el segundo cáncer más común y sigue siendo la principal causa de muerte por cáncer en los Estados Unidos. Sin embargo, una variedad de nuevos tratamientos, muchos de ellos desarrollados o probados en el Memorial Sloan Kettering Cancer Center (MSK), están

To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center.

… Saturday, January 1, 2011 Summary To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center. To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center. The goal of the new